Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la base de données des Annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
Triethanolamine oleate III SEP / 98
Triethanolamine salicylate in concentrations greater than 20% III SEP / 98
Triethanolamine salicylate. in concentrations up to and including 20% U
Trifluoperazine or its saltsPDL I DEC / 13
Triflupromazine or its saltsPDL I DEC / 13
TrifluridinePDL I DEC / 13
Trihexyphenidyl or its saltsPDL I DEC / 13
Triiodothyropropionic acidPDL I DEC / 13
TrilostanePDL I DEC / 13
Trimebutine or its saltsPDL I DEC / 13
TrimeperidineN I JUN / 02
Trimeprazine or its saltsPDL

for human use

I DEC / 13
TrimethadionePDL I DEC / 13
Trimethaphan camsylatePDL I DEC / 13
Trimethoprim or its saltsPDL I DEC / 13
Trimetrexate or its saltsPDL I DEC / 13
Trimipramine or its saltsPDL I DEC / 13
TrioxsalenPDL I DEC / 13
Tripelennamine and its salts III SEP / 98
Triprolidine III SEP / 98
Triptorelin or its salts or derivativesPDL I DEC / 13
TroglitazonePDL I DEC / 13
Tropicamide or its saltsPDL

in preparations for parenteral or ophthalmic use, except when sold for use in diagnostic procedures to an optometrist registered in a province of Canada for human use

I DEC / 13
Tropicamide or its saltsPDL

For veterinary use

I DEC / 13
Trospium chloridePDL I DEC / 13
Trovafloxacin or its salts or derivativesPDL

including but not limited to alatrofloxacin

I DEC / 13
Trypsin U DEC / 98
Tubocurarine chloridePDL I DEC / 13
TulathromycinPDL

For veterinary use

I DEC / 13
TybamatePDL I DEC / 13
Tylosin or its salts or derivativesPDL

Including but not limited to: Tildipirosin, tilmicosin, tylvalosin

I DEC / 18
Typhoid vaccines/Salmonella Typhi vaccines I FEB / 02
Tyrothricine III SEP / 98
Ubiquinone U DEC / 98
Ulipristal or its salts or derivativesPDL

Including but not limited to Ulipristal or its salts or derivatives.

I DEC / 13
Umeclidinium or its salts or derivativesPDL I FEB / 14
Uracil and its saltsF1 when sold for the treatment of cancer I DEC / 11
Uracil mustard or its saltsPDL I DEC / 13
Urea in topical preparations in concentrations of more than 25% II SEP / 98
UrokinasePDL I DEC / 13
Ursodeoxycholic acid or its saltsPDL I DEC / 13
UstekinumabPDL I DEC / 13
Vaccines (except for - those which are part of a routine immunization program in most/all provinces and territories: Diphtheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus) I FEB / 02
Vaccines. which are part of a routine immunization program in most/all provinces and territories: Diptheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus II FEB / 02
Valaciclovir or its saltsPDL I DEC / 13
Valdecoxib or its saltsPDL I DEC / 13
Valganciclovir or its salts or derivativesPDL I DEC / 13
Valproic acid or its saltsPDL

Including but not limited to Divalproex sodium

I DEC / 13
Valrubicin or its derivativesPDL I DEC / 13
Valsartan or its salts or derivativesPDL I DEC / 13
Vancomycin or its salts or derivativesPDL

including but not limited to Telavancin

I DEC / 13
Vandetanib or its salts or derivativesPDL I DEC / 13
Vardenafil or its saltsPDL I DEC / 13
Varenicline or its saltsPDL I DEC / 13
Varicella Zoster immune globulin I FEB / 02
Varicella vaccine (chicken pox) I FEB / 02
Vasopressin or its saltsPDL I DEC / 13
Vecuronium bromidePDL I DEC / 13
Vedaprofen or its salts or derivativesPDL I DEC / 13
VedolizumabPDL I MAR / 15
Vegetable tar except shampoos in concentrations of 5% or less III SEP / 98
Velaglucerase alfaPDL I DEC / 13
VelpatasvirPDL I AUG / 16
Vemurafenib or its salts or derivativesPDL I DEC / 13
Venetoclax or its saltsPDL I NOV / 16
Venlafaxine or its saltsPDL I DEC / 13
Verapamil or its saltsPDL I DEC / 13
Veratrum album or its alkaloids or their saltsPDL

for human use

I DEC / 13
Veratrum viride or its alkaloids or their saltsPDL

For human use

I DEC / 13
Vernakalant or its saltsPDL I APR / 17
Verteporfin or its salts or derivatives PDL I DEC / 13
VidarabinePDL I DEC / 13
Vigabatrin or its salts or derivativesPDL I DEC / 13
Vilanterol or its saltsPDL

Including but not limited to Vilanterol trifenatate

I DEC / 13
Vilazodone or its saltsPDL I AUG / 15
VinbarbitalC2 I JUN / 02
Vinblastine or its saltsPDL I DEC / 13
Vincristine or its saltsPDL I DEC / 13
Vindesine or its saltsPDL I DEC / 13
Vinorelbine or its saltsPDL I DEC / 13
VinylbitalC2 I JUN / 02
Viomycin or its salts or derivativesPDL I DEC / 13
Virginiamycin or its salts or derivativesPDL I DEC / 18
VismodegibPDL I DEC / 13
Vitamin APDL

in oral dosage forms containing more than 10,000 International Units of Vitamin A per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 10,000 International Units of Vitamin A for human use

I DEC / 13
Vitamin B12 with Intrinsic Factor ConcentratePDL I DEC / 13
Vitamin DPDL

For human use in oral dosage form containing more than 1,000 International Units of Vitamin D per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 1,000 International Units of Vitamin D

I DEC / 13
Vitamin KPDL

except Vitamin K1 and Vitamin K2 sold (a) for external use in humans; or (b) in an oral dosage form for use in humans if the maximum recommended daily dose is 0.120 mg or less For human use

I DEC / 13
Vitamins any parenterals not otherwise included in Schedule I II SEP / 98
Vitamins in injectable form for parenteral nutrition I JAN / 03
Vorapaxar or its saltsPDL I AUG / 16
VoriconazolePDL I DEC / 13
VorinostatPDL I DEC / 13
Vortioxetine or its saltsPDL

including but not limited to vortioxetine hydrobromide

I DEC / 14
Voxilaprevir or its saltsPDL I SEP / 17
Xanthinol nicotinatePDL I DEC / 13
Xylazine or its saltsPDL I DEC / 13
Xylometazoline and it salts in nasal preparations for pediatric use (0.05%) II SEP / 98
Xylometazoline and its salts in nasal preparations for adults (0.1%) U
Xylose II SEP / 98

2022 résultats


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled